1.
Clin Infect Dis
; 70(5): 943-946, 2020 02 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31804669
RESUMO
We evaluated an elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide single-tablet regimen for human immunodeficiency virus postexposure prophylaxis. The completion rate and adherence were good, and the tolerance was acceptable; no seroconversion was observed. We confirm that this regimen could be appropriate for postexposure prophylaxis. CLINICAL TRIALS REGISTRATION: NCT02998320.